As a normal antiviral immunotherapy, convalescent plasma therapy was evaluated by clinical tests in China through the early onset from the pandemic (95), and subsequently authorized to be utilized for critically ill individuals with COVID-19 under EUA in america (96, 97). inflammatory and response cell loss of life systems including NETs, pyrolysis, pANoptosis and apoptosis […]